SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (ILMN) today announced that GeneDx, a leader in genetic testing for rare diseases, is piloting Illumina's emerging constellation mapped read ...

Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (ILMN) today announced the launch of BioInsight, a ...

Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc.

40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing ...

When Illumina (ILMN) announced its acquisition of Fluent BioSciences, it did not say how much it shelled out for the privately held single-cell technology developer in a deal that catapulted the ...

SAN DIEGO, June 24, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the successful completion of the spin-off of GRAIL. This milestone follows the company's previously announced ...

During the meeting, Steve Barnard, PhD, Illumina’s CTO will provide new details about the company’s constellation mapped read technology. He will be joined by Niall Lennon, PhD, chair and CSO of Broad ...

In this episode we are joined by Damon Hostin, Lead, Health System Market Access at Illumina, in discussing how genomics informs healthcare. Tune in to hear about how knowledge obtained through ...

Illumina lowered its annual financial forecast and says it plans to cut about $100 million in costs after China banned imports of its gene sequencers last week. The San Diego maker of gene-sequencing ...

SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Laboratory Services, Illumina's CLIA-certified laboratory, is providing clinical sequencing and ...